2',3',4',5'-tetracetyl-3-(2-iodoethyl)riboflavin | 929540-54-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 2',3',4',5'-tetracetyl-3-(2-iodoethyl)riboflavin
• CAS: 929540-54-5
• 化学式: C₂₇H₃₁IN₄O₁₀
• 分子量: 698.468
• InChiKey: JPHPYRXPXSBVIA-ZDXQCDESSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.47
• 重原子数：
  42.0
• 可旋转键数：
  11.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  174.98
• 氢给体数：
  0.0
• 氢受体数：
  14.0

反应信息

• 作为反应物：
  描述：

  2',3',4',5'-tetracetyl-3-(2-iodoethyl)riboflavin 、 (S)-(+)-布洛芬 在 三乙胺 作用下， 以 丙酮 为溶剂， 以26%的产率得到2',3',4',5'-tetracetyl-3-{2-{[1-(4-isobutylphenyl)ethyl]carbonyloxy}ethyl}riboflavin
  参考文献：
  名称：

  Synthesis and biological activities of novel dexibuprofen tetraacetylriboflavin conjugates

  摘要：

  A series of novel dexibuprofen derivatives covalently linked via alkylene spacers of variable length to tetraacetylated riboflavin have been developed. The target compounds became accessible by reaction of the chloromethyl ester of dexibuprofen with tetraacetylriboflavin (compound 7) or by synthesis of the appropriate N3-(omega-iodoalkyl)-2',3',4',5'-tetraacetylriboflavin followed by treatment with dexibuprofen (derivatives 8-11), respectively. Biological screening revealed that the target compounds exhibit antiproliferative effects on MCF-7 breast cancer and HT-29 colon carcinoma cells with IC(50) values in the range of 8-15 VM. Enzymatic studies on human platelets indicated significant COX-1 inhibitory activities of the target compounds. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.087
• 作为产物：
  描述：

  核黄素,2',3',4',5'-四乙酸酯 在 吡啶 、 potassium carbonate 、 sodium iodide 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 5.0h， 生成 2',3',4',5'-tetracetyl-3-(2-iodoethyl)riboflavin
  参考文献：
  名称：

  Synthesis and biological activities of novel dexibuprofen tetraacetylriboflavin conjugates

  摘要：

  A series of novel dexibuprofen derivatives covalently linked via alkylene spacers of variable length to tetraacetylated riboflavin have been developed. The target compounds became accessible by reaction of the chloromethyl ester of dexibuprofen with tetraacetylriboflavin (compound 7) or by synthesis of the appropriate N3-(omega-iodoalkyl)-2',3',4',5'-tetraacetylriboflavin followed by treatment with dexibuprofen (derivatives 8-11), respectively. Biological screening revealed that the target compounds exhibit antiproliferative effects on MCF-7 breast cancer and HT-29 colon carcinoma cells with IC(50) values in the range of 8-15 VM. Enzymatic studies on human platelets indicated significant COX-1 inhibitory activities of the target compounds. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.087